In a sector note on U.S. Medical Supplies and Devices, UBS initiated coverage of Baxter with a Neutral rating and $43 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAX:
- Thermo Fisher, Celltrion compete for Baxter’s biopharma unit, Reuters says
- Baxter treatment of short bowel syndrome granted FDA orphan designation
- Baxter call volume above normal and directionally bullish
- Baxter price target lowered to $54 from $63 at Barclays
- Baxter price target lowered to $45 from $70 at Cowen